West Pharmaceutical Services, Inc.
WST
$355.64
$1.530.43%
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -2.96% | 3.29% | 8.81% | -2.27% | -0.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.96% | 3.29% | 8.81% | -2.27% | -0.47% |
| Cost of Revenue | 4.47% | 1.46% | 9.60% | 2.78% | 2.27% |
| Gross Profit | -15.15% | 6.41% | 7.57% | -9.33% | -4.67% |
| SG&A Expenses | 0.81% | 154.34% | -23.01% | 8.61% | 3.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -25.00% | 8.33% | -133.33% | 175.00% | 114.29% |
| Total Operating Expenses | 3.83% | 13.02% | 2.69% | 4.09% | 3.43% |
| Operating Income | -25.15% | -19.20% | 33.21% | -17.60% | -11.40% |
| Income Before Tax | -19.50% | 30.02% | 35.25% | -18.39% | -16.10% |
| Income Tax Expenses | -30.51% | 19.38% | 44.12% | -21.27% | 11.32% |
| Earnings from Continuing Operations | -17.64% | 33.01% | 33.75% | -17.72% | -19.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.64% | 33.01% | 33.75% | -17.72% | -19.45% |
| EBIT | -25.15% | -19.20% | 33.21% | -17.60% | -11.40% |
| EBITDA | -19.16% | -14.80% | 30.82% | -13.97% | -8.95% |
| EPS Basic | -16.52% | 33.55% | 33.92% | -17.61% | -19.55% |
| Normalized Basic EPS | -22.88% | -17.97% | 32.98% | -16.38% | -10.64% |
| EPS Diluted | -16.22% | 33.40% | 34.59% | -16.94% | -19.21% |
| Normalized Diluted EPS | -22.48% | -17.65% | 33.51% | -16.05% | -10.17% |
| Average Basic Shares Outstanding | -1.34% | -0.40% | -0.13% | -0.13% | 0.13% |
| Average Diluted Shares Outstanding | -1.85% | -0.79% | -0.53% | -0.53% | -0.39% |
| Dividend Per Share | 5.26% | 5.26% | 5.56% | 5.56% | 5.56% |
| Payout Ratio | 0.27% | -0.21% | -0.22% | 0.31% | 0.31% |
